201 related articles for article (PubMed ID: 3768528)
21. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.
Patscheke H; Stegmeier K
Thromb Res; 1984 Feb; 33(3):277-88. PubMed ID: 6424261
[TBL] [Abstract][Full Text] [Related]
22. Protein kinase C activation is not a key step in ADP-mediated exposure of fibrinogen receptors on human platelets.
Pulcinelli FM; Ashby B; Gazzaniga PP; Daniel JL
FEBS Lett; 1995 May; 364(1):87-90. PubMed ID: 7772199
[TBL] [Abstract][Full Text] [Related]
23. Exposure of platelet fibrinogen receptors by zinc ions: role of protein kinase C.
Trybulec M; Kowalska MA; McLane MA; Silver L; Lu W; Niewiarowski S
Proc Soc Exp Biol Med; 1993 May; 203(1):108-16. PubMed ID: 8475131
[TBL] [Abstract][Full Text] [Related]
24. Pretreatment of human platelets with plasmin inhibits responses to thrombin, but potentiates responses to low concentrations of aggregating agents, including the thrombin receptor activating peptide, SFLLRN.
Kinlough-Rathbone RL; Perry DW; Rand ML; Packham MA
Thromb Haemost; 1997 Apr; 77(4):741-7. PubMed ID: 9134653
[TBL] [Abstract][Full Text] [Related]
25. Fibrinogen binding to human blood platelets: effect of gamma chain carboxyterminal structure and length.
Peerschke EI; Francis CW; Marder VJ
Blood; 1986 Feb; 67(2):385-90. PubMed ID: 3942829
[TBL] [Abstract][Full Text] [Related]
26. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways.
Krishnamurthi S; Westwick J; Kakkar VV
Biochem Pharmacol; 1984 Oct; 33(19):3025-35. PubMed ID: 6091666
[TBL] [Abstract][Full Text] [Related]
27. Stimulus-response coupling in human platelets activated by monoclonal antibodies to the CD9 antigen, a 24 kDa surface-membrane glycoprotein.
Carroll RC; Worthington RE; Boucheix C
Biochem J; 1990 Mar; 266(2):527-35. PubMed ID: 2317202
[TBL] [Abstract][Full Text] [Related]
28. Studies on the mechanism of bacterial resistance to complement-mediated killing. I. Terminal complement components are deposited and released from Salmonella minnesota S218 without causing bacterial death.
Joiner KA; Hammer CH; Brown EJ; Cole RJ; Frank MM
J Exp Med; 1982 Mar; 155(3):797-808. PubMed ID: 6801179
[TBL] [Abstract][Full Text] [Related]
29. Activation of human platelets by N-substituted aminophospholipids.
Martin TW; Joist JH; Bauman JE; Lagunoff D
J Biol Chem; 1985 Mar; 260(5):2852-6. PubMed ID: 2982840
[TBL] [Abstract][Full Text] [Related]
30. Zinc-induced platelet aggregation is mediated by the fibrinogen receptor and is not accompanied by release or by thromboxane synthesis.
Heyns Adu P; Eldor A; Yarom R; Marx G
Blood; 1985 Jul; 66(1):213-9. PubMed ID: 2988668
[TBL] [Abstract][Full Text] [Related]
31. The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets.
Gartner TK; Bennett JS
J Biol Chem; 1985 Oct; 260(22):11891-4. PubMed ID: 2995350
[TBL] [Abstract][Full Text] [Related]
32. The fibrinogen-derived peptide (RGDS) prevents proteolytic degradation of protein kinase C in platelets by inhibiting platelet aggregation.
Krishnamurthi S; Dickens TA; Patel Y; Wheeler-Jones CP; Kakkar VV
Biochem Biophys Res Commun; 1989 Sep; 163(3):1256-64. PubMed ID: 2783136
[TBL] [Abstract][Full Text] [Related]
33. Reactions of polylysine with human platelets in plasma and in suspensions of washed platelets.
Guccione MA; Packham MA; Kinlough-Rathbone RL; Perry DW; Mustard JF
Thromb Haemost; 1976 Nov; 36(2):360-75. PubMed ID: 827032
[TBL] [Abstract][Full Text] [Related]
34. Ca+2 mobilization and fibrinogen binding of platelets refractory to adenosine diphosphate stimulation.
Peerschke EI
J Lab Clin Med; 1985 Aug; 106(2):111-22. PubMed ID: 2991399
[TBL] [Abstract][Full Text] [Related]
35. Benzodiazepines inhibit human platelet activation: comparison of the mechanism of antiplatelet actions of flurazepam and diazepam.
Romstedt K; Huzoor-Akbar
Thromb Res; 1985 May; 38(4):361-74. PubMed ID: 2990062
[TBL] [Abstract][Full Text] [Related]
36. Effects of cathepsin G pretreatment of platelets on their subsequent responses to aggregating agents.
Kinlough-Rathbone RL; Perry DW; Rand ML; Packham MA
Thromb Res; 1999 Sep; 95(6):315-23. PubMed ID: 10527409
[TBL] [Abstract][Full Text] [Related]
37. Exposure of platelet fibrinogen-binding sites by collagen, arachidonic acid, and ADP: inhibition by a monoclonal antibody to the glycoprotein IIb-IIIa complex.
Di Minno G; Thiagarajan P; Perussia B; Martinez J; Shapiro S; Trinchieri G; Murphy S
Blood; 1983 Jan; 61(1):140-8. PubMed ID: 6216929
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of [3H]platelet activating factor (PAF) binding by Zn2+: a possible explanation for its specific PAF antiaggregating effects in human platelets.
Nunez D; Kumar R; Hanahan DJ
Arch Biochem Biophys; 1989 Aug; 272(2):466-75. PubMed ID: 2502069
[TBL] [Abstract][Full Text] [Related]
39. Human platelet activation by bacterial phospholipase C is mediated by phosphatidylinositol hydrolysis but not generation of phosphatidic acid: inhibition by a selective inhibitor of phospholipase C.
Navran SS; Romstedt K; Chang J; Miller DD; Feller DR; Huzoor-Akbar
Thromb Res; 1984 Mar; 33(5):499-510. PubMed ID: 6372157
[TBL] [Abstract][Full Text] [Related]
40. The inhibitory effects of exogenous arachidonic acid on rabbit platelet aggregation and the release reaction.
Cattaneo M; Kinlough-Rathbone RL; Perry DW; Chahil A; Vickers JD; Lam SC; Packham MA; Mustard JF
Blood; 1982 Nov; 60(5):1179-87. PubMed ID: 6289942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
